Impaired HBsAg release and antiproliferative/antioxidant cell regulation by HBeAg ‐negative patient isolates reflects an evolutionary process
2024; Wiley; Volume: 44; Issue: 10 Linguagem: Inglês
10.1111/liv.16048
ISSN1478-3231
AutoresMichael Basic, Keerthihan Thiyagarajah, Mirco Glitscher, Anja Schollmeier, Qingyan Wu, Esra Görgülü, Pia Lembeck, Jannik Sonnenberg, Julia Dietz, Fabian Finkelmeier, Michael Praktiknjo, Jonel Trebicka, Stefan Zeuzem, Christoph Sarrazin, Eberhard Hildt, Kai‐Henrik Peiffer,
Tópico(s)Hepatitis C virus research
ResumoThe hepatitis B e antigen (HBeAg)-negative infection Phase 3 is characterized by no or minimal signs of hepatic inflammation and the absence of hepatic fibrosis. However, underlying molecular mechanisms leading to this benign phenotype are poorly understood.
Referência(s)